Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) EBT (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported EBT over the past 16 years, most recently at -$1.1 million for Q2 2025.

  • Quarterly results put EBT at -$1.1 million for Q2 2025, up 84.4% from a year ago — trailing twelve months through May 2025 was -$38.7 million (down 506.5% YoY), and the annual figure for FY2025 was -$38.7 million, down 506.5%.
  • EBT for Q2 2025 was -$1.1 million at Lifecore Biomedical, Inc. \De\, up from -$14.8 million in the prior quarter.
  • Over the last five years, EBT for LFCR hit a ceiling of $15.0 million in Q1 2024 and a floor of -$36.8 million in Q2 2023.
  • Median EBT over the past 5 years was -$7.3 million (2022), compared with a mean of -$7.6 million.
  • Biggest five-year swings in EBT: tumbled 8527.43% in 2021 and later skyrocketed 254.15% in 2023.
  • Lifecore Biomedical, Inc. \De\'s EBT stood at $1.3 million in 2021, then plummeted by 823.03% to -$9.2 million in 2022, then skyrocketed by 254.15% to $14.2 million in 2023, then tumbled by 146.05% to -$6.5 million in 2024, then soared by 82.94% to -$1.1 million in 2025.
  • The last three reported values for EBT were -$1.1 million (Q2 2025), -$14.8 million (Q1 2025), and -$6.5 million (Q4 2024) per Business Quant data.